The Administrative Burden of Overactive Bladder Medications

Area of Science:

• Urology
• Pharmacology
• Health Services Research

Background:

• Overactive bladder (OAB) treatment guidelines recommend trospium and beta-3 agonists as preferred medications.
• These preferred OAB medications often require additional insurance pre-approval steps, potentially impacting patient care.
• The administrative burden associated with preferred OAB medications is not well-quantified.

Purpose of the Study:

• To evaluate the administrative burden and delay of care for preferred OAB medications versus nonpreferred alternatives.
• To test the hypothesis that preferred OAB medications incur higher administrative costs and longer treatment initiation times.

Main Methods:

• A single-center mixed-methods study combining retrospective chart review and prospective observation of clinical staff.
• Retrospective analysis of 200 adult women initiating OAB therapy, collecting data on medication approval processes.
• Prospective observation of 13 clinical staff members to record time spent on OAB medication approval tasks.

Main Results:

• Prescribing preferred OAB medications resulted in significantly more messages (3±7 vs. 0±0) and longer time to approval (17±36 days vs. 0±0 days) compared to nonpreferred options.
• Each preferred OAB medication prescription required an estimated 38 minutes of additional administrative time.
• Prior authorizations and appeals represented the most time-consuming approval tasks.

Conclusions:

• Preferred OAB medications are associated with significantly greater administrative burden and delays in patient care.
• Expanded insurance coverage and streamlined prior authorization processes are needed for preferred OAB treatments.
• Addressing administrative barriers can improve patient access to guideline-recommended OAB therapies.